FDA approves Pfizer Nivestym, second Neupogen biosimilar

By Allison Johnson | Jul 27, 2018 | 3:27 PM GMT

FDA approved Nivestym filgrastim-aafi from Pfizer Inc. (NYSE:PFE), its biosimilar version of neutropenia drug Neupogen

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE